UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions

Gynecologic oncology, 2015-01, Vol.136 (1), p.3-7

2015

Volltextzugriff (PDF)

Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology

Gynecologic oncology reports, 2023-04, Vol.46, p.101148-101148, Article 101148

Richardson, Debra L.

2023

Volltextzugriff (PDF)

Influence of Intraoperative Capsule Rupture on Outcomes in Stage I Epithelial Ovarian Cancer

Obstetrics and gynecology (New York. 1953), 2009-01, Vol.113 (1), p.11-17

2009

Volltextzugriff (PDF)

The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform

Gynecologic oncology, 2009-01, Vol.112 (1), p.55-59

2009

Volltextzugriff (PDF)

Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062)

Molecular cancer therapeutics, 2020-11, Vol.19 (11), p.2363-2370

2020

Volltextzugriff (PDF)

A detailed analysis of the learning curve: Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer

Gynecologic oncology, 2009-08, Vol.114 (2), p.162-167

2009

Volltextzugriff (PDF)

Should we or should we not? Secondary debulking in ovarian cancer

The lancet oncology, 2021-04, Vol.22 (4), p.412-413

Richardson, Debra L

2021

Volltextzugriff (PDF)

Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer

Hematology/oncology clinics of North America, 2018-12, Vol.32 (6), p.1057-1071

2018

Volltextzugriff (PDF)

Targeting NaPi2b in ovarian cancer

Cancer treatment reviews, 2023-01, Vol.112, p.102489-102489, Article 102489

2023

Volltextzugriff (PDF)

The emerging use of antibody-drug conjugates in ovarian cancer

Clinical advances in hematology & oncology, 2023-05, Vol.21 (5), p.244

Richardson, Debra L

2023

Volltextzugriff (PDF)

Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer

Gynecologic oncology, 2006-11, Vol.103 (2), p.667-672

2006

Volltextzugriff (PDF)

Is there a role for secondary debulking in ovarian cancer? A review of the current literature

Current opinion in obstetrics & gynecology, 2023-02, Vol.35 (1), p.1-5

2023

Volltextzugriff (PDF)

Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer

American journal of clinical oncology, 2018-10, Vol.41 (10), p.933-937

2018

Volltextzugriff (PDF)

Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications

Obstetrics and gynecology (New York. 1953), 2016-03, Vol.127 (3), p.468-473

2016

Volltextzugriff (PDF)

New and Novel Therapies for Gynecologic Cancers

Seminars in oncology nursing, 2019-04, Vol.35 (2), p.217-219

Richardson, Debra L.

2019

Volltextzugriff (PDF)

Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review

JAMA oncology, 2023-06, Vol.9 (6), p.851

2023

Volltextzugriff (PDF)

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer

Gynecologic oncology, 2011-05, Vol.121 (2), p.269-272

2011

Volltextzugriff (PDF)

OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab

Gynecologic oncology, 2022-08, Vol.166 (2), p.219-229

2022

Volltextzugriff (PDF)

Advances in antibody-drug conjugates for gynecologic malignancies

Current opinion in obstetrics & gynecology, 2023-02, Vol.35 (1), p.6-14

2023

Volltextzugriff (PDF)

Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer

Gynecologic oncology, 2008-12, Vol.111 (3), p.461-466

2008

Volltextzugriff (PDF)

Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2024-10, Vol.42 (29), p.3443-3452

2024

Volltextzugriff (PDF)

Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice

Clinical cancer research, 2024-10, Vol.30 (20), p.4644-4653

2024

Volltextzugriff (PDF)

Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic oncology, 2017-09, Vol.146 (3), p.477-483

2017

Volltextzugriff (PDF)

Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer

Gynecologic oncology, 2024-06, Vol.185, p.186-193

2024

Volltextzugriff (PDF)

Olaparib in the treatment of ovarian cancer

Future oncology (London, England), 2019-10, Vol.15 (30), p.3435-3449

2019

Volltextzugriff (PDF)

1 – 25 von 243

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(222)
Mit Volltextzugriff
(195)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(146)
Life Sciences & Biomedicine
(128)
Humans
(112)
Female
(91)
Middle Aged
(52)
Oncology
(52)
Adult
(44)
Obstetrics & Gynecology
(43)
Aged
(34)
Male
(31)
Obstetrics And Gynecology
(25)
Hematology, Oncology And Palliative Medicine
(24)
Retrospective Studies
(21)
Biological And Medical Sciences
(20)
Medical Sciences
(19)
Ovarian Cancer
(19)
Ovarian Neoplasms - Drug Therapy
(19)
Chemotherapy
(18)
Aged, 80 And Over
(17)
Adolescent
(14)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Ingenta
(135)
Journals@Ovid Full Text
(119)
MEDLINE
(116)
EZB Electronic Journals Library
(105)
Publisher or Other Site
(73)
IngentaConnect Journals
(66)
ScienceDirect
(63)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(45)
Wiley Online Library
(27)
BMJ Journals
(15)
JSTOR
(12)
Wiley Online Library Full Collection 2018
(11)
Oxford journals
(9)
Association for Computing Machinery
(7)
Oxford Journals 2020 Medicine
(6)
Springer Online Journals
(6)
IEEE
(5)
Taylor & Francis
(5)
Taylor & Francis Online
(4)
Sociological Abstracts
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions

Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology

Influence of Intraoperative Capsule Rupture on Outcomes in Stage I Epithelial Ovarian Cancer

The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform

Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062)

A detailed analysis of the learning curve: Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer

Should we or should we not? Secondary debulking in ovarian cancer

Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer

Targeting NaPi2b in ovarian cancer

The emerging use of antibody-drug conjugates in ovarian cancer

Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer

Is there a role for secondary debulking in ovarian cancer? A review of the current literature

Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer

Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications

New and Novel Therapies for Gynecologic Cancers

Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer

OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab

Advances in antibody-drug conjugates for gynecologic malignancies

Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer

Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors

Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice

Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer

Olaparib in the treatment of ovarian cancer

Suchergebnisse filtern